Kerrisdale Advisers, LLC Delcath Systems, Inc. Transaction History
Kerrisdale Advisers, LLC
- $221 Million
- Q1 2025
A detailed history of Kerrisdale Advisers, LLC transactions in Delcath Systems, Inc. stock. As of the latest transaction made, Kerrisdale Advisers, LLC holds 36,645 shares of DCTH stock, worth $507,533. This represents 0.21% of its overall portfolio holdings.
Number of Shares
36,645
Previous 66,645
45.01%
Holding current value
$507,533
Previous $785,000
40.64%
% of portfolio
0.21%
Previous 0.29%
Shares
3 transactions
Others Institutions Holding DCTH
# of Institutions
104Shares Held
12.1MCall Options Held
79KPut Options Held
53.3K-
Vanguard Group Inc Valley Forge, PA1.39MShares$19.3 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY813KShares$11.3 Million0.26% of portfolio
-
Vivo Capital, LLC Palo Alto, CA750KShares$10.4 Million2.59% of portfolio
-
Exodus Point Capital Management, LP New York, NY699KShares$9.69 Million0.09% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA557KShares$7.72 Million0.0% of portfolio
About DELCATH SYSTEMS, INC.
- Ticker DCTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 8,597,680
- Market Cap $119M
- Description
- Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...